Lobe Sciences Announces Proposed Shares for Debt Transaction Jun 1, 2026 10:00PM
Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York May 6, 2026 08:00PM
Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress May 6, 2026 06:00AM
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders Apr 23, 2026 08:00AM
Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services Apr 21, 2026 06:00AM


Apr 20, 2026 06:04AM Lobe Sciences closes $950,000 private placement for drug development
Apr 20, 2026 06:00AM Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
Apr 10, 2026 08:00PM Lobe Sciences announces $950,000 private placement offering
Apr 10, 2026 08:00PM Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Mar 25, 2026 08:20AM Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
Mar 9, 2026 12:00AM Lobe Sciences names Mirza Rahimani as chief financial officer
Mar 9, 2026 12:00AM Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
Mar 5, 2026 07:40AM Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Feb 3, 2026 07:00AM Lobe Sciences Reports First Quarter 2026 Results and Highlights
Jan 13, 2026 07:00AM Lobe Sciences appoints Nick Karakochuk to board of directors
Jan 13, 2026 07:00AM Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
Jan 8, 2026 08:55AM Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
Jan 6, 2026 06:00AM Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
Oct 23, 2025 11:50PM Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
Oct 9, 2025 06:50AM Lobe Sciences Improves Balance Sheet
Sep 15, 2025 11:50PM Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
Sep 9, 2025 11:50PM Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
Sep 9, 2025 12:01AM Lobe Sciences appoints Marco Mastrodonato to board of directors
Sep 8, 2025 11:50PM Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
Aug 14, 2025 11:00PM Lobe Sciences closes private placement raising $341,425 CAD
Aug 14, 2025 11:00PM Lobe Sciences Announces the Closing of the Previously Announced Private Placement
Jul 29, 2025 12:10AM Lobe Sciences raises C$341,425 through private placement
Jul 29, 2025 12:10AM Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes
Jul 29, 2025 12:08AM Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
Jul 16, 2025 09:55PM Lobe Sciences Ltd. Announces Debt Settlement
Jul 8, 2025 12:01AM Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
Jun 17, 2025 11:58PM Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
Jun 3, 2025 06:10AM Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Apr 14, 2025 07:00AM Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Apr 4, 2025 11:50PM Lobe Sciences Provides Corporate Update